Valeant Pharmaceuticals (VRX) Posts Q1 EPS of 99c; Boosts FY12 Outlook
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.99, versus $0.02 reported in the same period last year.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.45-$4.70, versus prior guidance of $3.95-$4.20. Valeant Pharmaceuticals International, Inc. sees FY2012 revenue of $3.4-$3.6 billion.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.45-$4.70, versus prior guidance of $3.95-$4.20. Valeant Pharmaceuticals International, Inc. sees FY2012 revenue of $3.4-$3.6 billion.
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Royal Unibrew reports higher interim first-half profit as margins improve
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
